Gene therapy for limb girdle muscular dystrophy (LGMD) — the AAV-based viral vector approaches delivering functional genes to restore sarcoglycan, dystroglycan, and FKRP protein expression representing the first potentially disease-modifying treatments — creates the most commercially transformative market segment, with the Limb Girdle Muscular Dystrophy Market reflecting gene...